Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

• Revenue in USD (TTM)0.00
• Net income in USD-47.17m
• Incorporated2006
• Employees35.00

• Location
  Aptose Biosciences Inc251 Consumers Rd Suite 1105NORTH YORK M2J 4R3CanadaCAN
• Phone+1 (647) 479-9828
• Fax+1 (416) 798-2200
• Websitehttps://aptose.com/